Get started
Author

Udit Yadav

Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma
2025 · Kenneth J. C. Lim, Melinda Tan, et al. · Blood Cancer Journal · 19
PDF
Venetoclax-based treatment combinations in relapsed/refractory multiple myeloma: practice patterns and impact of secondary cytogenetic abnormalities on outcomes
2025 · Abiola Bolarinwa, Madhu Nagaraj, et al. · Blood Cancer Journal · 11
PDF
Diagnosis and management of immune effector cell–associated enterocolitis after ciltacabtagene autoleucel
2026 · Kenneth J. C. Lim, Hee Eun Lee, et al. · Blood Advances · 4
PDF
Management of hematological toxicities after BCMA-directed CAR-T cell therapy
2026 · Joselle Cook, Supriya Gupta, et al. · Blood Cancer Journal · 4
PDF
Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
2024 · Adrian A Almodovar Diaz, Samhar Alouch, et al. · Blood · 4
Investigating the Role of Dexamethasone Prophylaxis for the Risk Reduction of Immune Effector Cell Delayed Neurotoxicity in Cilta-Cel Treated Patients
2026 · Kenneth Jin Chang Lim, Ricardo Daniel Parrondo, et al. · Transplantation and Cellular Therapy · 2
CAR T-cell therapy outcomes in plasma cell leukemia
2026 · Melinda Tan, Joselle Cook, et al. · Blood Immunology & Cellular Therapy · 2
Early Treatment Failure in Patients Receiving Ciltacabtagene‐Autoleucel for Relapsed/Refractory Multiple Myeloma
2026 · Kenneth J. C. Lim, Shaji Kumar, et al. · American Journal of Hematology · 1
PDF
A multicenter study of progression risk and outcomes in solitary bone plasmacytoma with and without marrow involvement
2026 · Kenneth J. C. Lim, Maximilian Steinhardt, et al. · Blood Advances · 1
PDF
AIns (insulin) type amyloidosis in a kidney transplant candidate with a newly identified monoclonal gammopathy
2026 · Carlos Villarroel, Matthew Howard, et al. · Journal of Hematopathology · 1
Defining the proteome of bone marrow plasma in multiple myeloma and monoclonal gammopathy of undetermined significance
2025 · Joel-Sean Hsu, Udit Yadav, et al. · Blood Cancer Journal · 1
PDF
OA-41 Mitigating Cilta-cel-Associated Delayed Neurotoxicity in Patients with High Lymphocyte Expansion: A Prospective Observational Comparative Study of Prophylactic Cyclophosphamide
2026 · Christoph Schaefers, Melinda Tan, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-328 Outcomes of Multiple Myeloma with an Isolated Bone Lesion and Limited Marrow Involvement Treated with Localized Radiotherapy Alone
2026 · Daniel G. Packard, Udit Yadav, et al. · Clinical Lymphoma Myeloma & Leukemia
Prophylactic dexamethasone at the time of absolute lymphocyte expansion does not mitigate risk or event-free survival for immune effector cell associated delayed neurotoxicity
2026 · Kenneth JC Lim, Melinda Tan, et al. · Blood Cancer Journal
PDF
SOHO State-of-the-Art Updates and Next Questions: Current Approach to Waldenström Macroglobulinemia
2026 · Prashant Kapoor, Udit Yadav, et al. · Clinical Lymphoma Myeloma & Leukemia
Prospective Pilot Study of 11C-acetate and 18F-FDG with PET/CT and PET/MRI for Lesion Detection in Multiple Myeloma
2026 · Kristina Yancey, Will Han, et al. · Molecular Imaging and Biology
Real-world outcomes of newly diagnosed multiple myeloma patients treated with front-line daratumumab bortezomib lenalidomide and dexamethasone
2026 · Ricardo D. Parrondo, Ricardo De Menezes, et al. · Haematologica
PDF
Real-World Outcomes and Risk Factors in Multiple Myeloma Pts Receiving Cilta-Cel Including Functional High-Risk Status
2026 · Kenneth Jin Chang Lim, Ricardo Daniel Parrondo, et al. · Transplantation and Cellular Therapy
Bile cast nephropathy presenting as acute kidney injury in systemic light chain amyloidosis with severe hepatic involvement
2025 · Rodolfo Garza-Morales, Liying Fu, et al. · Amyloid
Real-World (RW) Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Front-Line Daratumumab (dara) Lenalidomide (len) and Dexamethasone (dex) (DRd)
2025 · Ricardo Parrondo, Leif Bergsagel, et al. · Clinical Lymphoma Myeloma & Leukemia
Abstract 4537: Dynamics of B-cell repertoires following CAR-T and bispecific antibody therapy in multiple myeloma
2025 · Feba Miriam Jacob, Rodolfo Garza-Morales, et al. · Cancer Research
Trial in Progress: Phase II Study Evaluating Maintenance in Light Chain Amyloidosis (EMILIA)
2024 · Aytaj Mammadzadeh, Madhu Nagaraj, et al. · Blood
Outcomes of Venetoclax-Based Treatment Combinations in Relapsed/Refractory Multiple Myeloma: Real-World Practice Patterns and Impact of Cytogenetics on Outcomes
2024 · Abiola Bolarinwa, Madhu Nagaraj, et al. · Blood
PDF
Real World Outcomes with Venetoclax (Ven)-Based Therapies in Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma (RRMM): A Mayo Clinic Comprehensive Cancer Center (MCCC) Experience
2024 · Ricardo D. Parrondo, Saurav Das, et al. · Blood
Racial disparities in the intervention trials in colon cancer.
2024 · Abhinav Vyas, Dania Kaur, et al. · Journal of Clinical Oncology
PDF
Works count: 26
Citation count: 51
H-index: 4
I10-index: 2
Year
Topic
Type